Elite Pharmaceuticals Announces Q1 FY2027 Results Conference Call

What Happened

• Elite Pharmaceuticals, Inc. filed an 8-K on August 10, 2026, reporting results of operations and financial condition and issuing a press release (Exhibit 99.1) announcing a conference call to discuss its first-quarter fiscal 2027 results for the period ended June 30, 2026. The filing also includes a Regulation FD disclosure about the press release and call.

Key Details

• Press release date: August 10, 2026; press release attached as Exhibit 99.1 to the 8-K.
• The filing states the company will host a conference call to discuss Q1 FY2027 results (ended June 30, 2026).
• Conference call timing is inconsistent in the filing: the release text says Thursday, November 14, 2026 at 11:30 AM EDT, while the conference-call info block lists Date: August 14, 2026 at 11:30 AM EDT.
• Dial-in numbers: 1-800-346-7359 (domestic) and 1-973-528-0008 (international); conference number: 98840. Questions contact: dianne@elitepharma.com. Deadlines in the filing: general questions by 5:00 PM EDT on Wednesday, November 12, 2026; financial questions by 7:00 PM EDT on Friday, November 13, 2026.
• The filing includes the boilerplate Regulation FD/Section 18 statement that the disclosure (and attached exhibit) is furnished, not “filed,” and is not incorporated by reference into other filings.

Why It Matters

• This 8-K signals that Elite will disclose quarterly earnings/operating results and will hold a live call for investors and analysts — events where revenue, earnings, and outlook details are typically provided. Because the filing contains conflicting call dates (Aug. 14 vs. Nov. 14), investors should confirm the correct date/time via the company’s investor relations or the attached press release before planning to participate. The press release exhibit will be the primary source for the official details.